Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers August 17, 2017
Pharmacy Choice - News - Over-the-Counter Drugs - August 17, 2017

Pharmacy News

 Over-the-Counter Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 236     Next >>     Go To Page:

7/18/17 - Allergic Rhinitis Market poised to grow at a CAGR of 7 % till 2023
Major Key Players are Merck, GSK, Sanofi, Cigna, Himalaya, J&J, Chong kun Dang Pharmaceutical Corp., Faes, Farma, Glenmark Pharmaceutical, " Market Research Future PUNE, MAHARASHTRA, INDIA, July 18, 2017/ EINPresswire.com/ Market Highlights Hay fever is another name for allergic rhinitis which is a nose related disease. The sale for anti-allerg
7/17/17 - Daiwa-SSI invests in CVI Pharma's ambition [Vietnam Investment Review (VIR)]
CVI Cosmetic& Pharmaceutical Co., JSC is partnering with Japanese Daiwa-SSI to venture further into the high-tech field with the ambition of becoming one of the top ten drug producers in Vietnam in the next five years. The facility valued at nearly VND300 billion will have an area of 1.1 hectares. For example, in the over-the-counter market, there
7/17/17 - Medication dosage errors increasing across U.S.: Study
Researchers found that the drugs most often associated with unintentional errors included cardiovascular drugs, analgesics and hormones/hormone antagonists like insulin from an analysis of 67,603 cases from the U.S. Poison Control Center between 2000 and 2013.. A third of the cases in the study resulted in hospital admission, and so they are
7/17/17 - Perrigo Announces FDA Final Approval For Its First-To-File Ab Rated Generic Version Of Androgel Topical Gel, 1.62% Packets
Perrigo Company plc today announced it has received final approval from the U.S. Food and Drug Administration for its AB rated Abbreviated New Drug Application referencing AbbVie Inc.' s Androgel Topical Gel, 1.62% packets. Annual market sales for Androgel Topical Gel, 1.62% packets for the 12 months ending May 2017 were approximately $88 m
7/17/17 - Perrigo Announces Settlement Of Generic Version Of Dymista Nasal Spray Patent Litigation
Perrigo Company plc today announced that it has settled the Hatch-Waxman litigation relating to Dymista nasal spray brought by Meda Pharmaceuticals Inc. and Cipla Ltd.. Annual market sales for the twelve months ending May 2017 were $152 million. About Perrigo Perrigo Company plc, a leading global healthcare company, delivers value to its custo
7/17/17 - Perrigo Confirms Patent Challenge For Generic Version Of Soolantra Cream, 1%
Perrigo Company plc today announced that its subsidiary has filed a Paragraph IV Abbreviated New Drug Application with the U.S. Food and Drug Administration for a generic version of Soolantra cream, 1%. Following notification from Perrigo, Galderma Laboratories, L.P., Galderma S.A., and Nestle Skin Health S.A., filed a patent litigation suit a
7/17/17 - Self-Administered Drugs Market Poised to Expand at a Robust Pace over 2024
New York, NY 07/17/2017 Self-administered drugs are mainly consumed by patients suffering from chronic diseases like multiple sclerosis, rheumatoid arthritis, diabetes and others. With the increasing number of people suffering from chronic diseases globally the self-administered drugs are expected to witness high demand, mainly among old and
7/14/17 - Intelligent Vending/Retail Systems and the Pharmaceutical Industry in Africa
Magex South Africa and PharmaAfrica24H have entered into a exclusive partnership to bring 24-hour intelligent retail and pharmaceutical vending platforms to Africa.
7/14/17 - Janssen Announces U.S. Fda Approval of Tremfya (Guselkumab) for Treatment of Moderate to Severe Plaque Psoriasis
Johnson and Johnson issued the following news release:. Janssen Biotech, Inc. announced today that the U.S. Food and Drug Administration has approved TREMFYA for the treatment of adults living with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. "TREMFYA represents a significant milestone in the treatme
7/14/17 - Novartis confirms 5 year data for first and only fully-human IL-17A inhibitor Cosentyx reinforcing sustained efficacy and safety profile in psoriasis
Novartis, a global leader in Immunology& Dermatology, confirmed today positive 5 year efficacy and safety results for Cosentyx from a Phase III long-term extension study in patients with moderate-to-severe plaque psoriasis. 1 Data will be presented at a key medical congress in the second half of 2017. 5 year Phase III data are a milestone for
7/14/17 - Rep. Blackburn, Kennedy Hearing Aid Bill Passes House
Marsha Blackburn, R- Tenn., issued the following news release:. Marsha Blackburn, R- Tenn., and Joe Kennedy III, D- Mass., on Wednesday applauded the passage of their bipartisan Over-the-Counter Hearing Aid Act in the U.S. House of Representatives. In addition, the legislation would require the FDA to write regulations ensuring that this new catego
7/14/17 - Reps. Kennedy, Blackburn Hearing Aid Bill Passes House
Joseph P. Kennedy III, D- Mass., issued the following news release:. Congressman Joe Kennedy III and Congressman Marsha Blackburn today applauded the bipartisan passage of their Over-the-Counter Hearing Aid Act in the House of Representatives. In addition, the legislation would require the FDA to write regulations ensuring that this new category of
7/13/17 - A New World of Microbiome Innovations: Microbiome Technologies Market Report 2017: Energizing Pharma and Life Sciences
The "Microbiome Technologies: Energizing Pharma and Life Sciences" report has been added to Research and Markets' offering. More than 50% of all Microbiome Research is Focused Towards the GI Multiple Diseases Have Unmet Therapeutics Needs Clostridium difficile Threat Increasing due to Increasing Antibiotic use Inflammatory Bowel Disease Another Lar
7/13/17 - BioPharmX To Present Phase 2b Clinical Trial Data at National DEF Essential Resource Meeting 2017
BioPharmX Corporation, a specialty pharmaceutical company focusing on dermatology, will present results of its phase 2 b research of BPX-01, a unique topical hydrophilic gel formulation of minocycline, at the Dermatology Education Foundation's Essential Resource Meeting, DERM 2017, being held July 20-23 in Las Vegas. e data, to be shared in a pos
7/13/17 - Blackburn, Kennedy Hearing Aid Bill Passes House
Marsha Blackburn, R- Tenn., and Joe Kennedy III, D- Mass., on Wednesday applauded the passage of their bipartisan Over-the-Counter Hearing Aid Act in the U.S. House of Representatives. In addition, the legislation would require the FDA to write regulations ensuring that this new category of OTC hearing aids meets the same high standards for safety,
7/13/17 - Contract Pharmacal Corp Converts Three Of Their Hauppauge Buildings To Solar Energy With SUNation Solar Systems
Hauppauge-based pharmaceutical company, Contract Pharmacal Corp, is leading the way in renewable energy for Long Island businesses by converting three of their buildings in the Hauppauge Industrial Park to run on solar energy. Contract Pharmacal Corp commissioned local solar installation company in Ronkonkoma, SUNation Solar Systems, to design 3
7/13/17 - HEALTH & SUPPORT
Held 7-8: 30 p.m. on the last Wednesday of each month in the doctors' conference room at Beverly Hospital, 85 Herrick St., Beverly. Financial counselors are available at Beverly Hospital, 85 Herrick St., Beverly, to assist you in accessing health insurance. Beverly Hospital is offering several American Heart Association CPR courses designed for non
7/13/17 - House Energy & Commerce Committee Issues Report on FDA Reauthorization Act
Greg Walden, R- Ore., on July 11. The Food and Drug Administration Reauthorization Act of 2017 enables FDA to continue to collect user fees from regulated industry to supplement Congressional appropriations. Since 1992, pursuant to PDUFA, Congress has authorized FDA to collect fees from regulated industry to supplement Congressional appropriations.
7/13/17 - Janssen Announces U.S. FDA Approval Of TREMFYA? (Guselkumab) For The Treatment Of Moderate To Severe Plaque Psoriasis
Janssen Biotech, Inc. announced today that the U.S. Food and Drug Administration has approved TREMFYA? for the treatment of adults living with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. "TREMFYA? represents a significant milestone in the treatment of moderate to severe plaque psoriasis as evi
7/13/17 - Microbiome Technologies Market 2017: Energizing Pharma and Life Sciences - Research and Markets
The "Microbiome Technologies: Energizing Pharma and Life Sciences" report has been added to Research and Markets' offering. More than 50% of all Microbiome Research is Focused Towards the GI Multiple Diseases Have Unmet Therapeutics Needs Clostridium difficile Threat Increasing due to Increasing Antibiotic use Inflammatory Bowel Disease Another Lar
7/13/17 - Rep. Green Legislation Passes House of Representatives
As the Ranking Member of the Energy and Commerce Subcommittee on Health, Congressman Green has worked on a bipartisan basis to pass a package of user fee agreements that will reauthorize key FDA capabilities to review and evaluate medical devices, brand and generic drugs, and biosimilar products. Although the current five-year FDA user fee agreemen
7/13/17 - Rep. Pallone Issues Remarks on Food, Drug Administration Reauthorization Act
"Mr. Speaker, I rise in support of H.R. 2430, the Food and Drug Administration Reauthorization Act- a bill that will allow the FDA to continue its critical mission of reviewing and approving drugs and medical devices that save lives and improve the quality of life for many Americans. The legislation before us today is the product of compromise and
7/13/17 - Rep. Pallone Leads Bipartisan Reauthorization of Food and Drug Administration User Fees Through the House
"The legislation before us today is the product of compromise and almost two years of work between FDA, Congress, industry, and other stakeholders," Pallone said during consideration of the bill on the House Floor earlier today. "The Food and Drug Administration Reauthorization Act, or FDARA, reauthorizes FDA's medical product user fee agreements,
7/13/17 - Rep. Upton, House Advance Critical Public Health, Jobs Bill
Fred Upton, R- Mich., issued the following news release:. Fred Upton, R- St. Joseph, today joined colleagues in the U.S. House of Representatives in advancing H.R. 2430, the FDA Reauthorization Act of 2017, by a unanimous vote. "Now that our groundbreaking 21st Century Cures Act is law, we need to make sure that the FDA is able to handle new break
7/12/17 - BioDelivery Sciences Signs Exclusive Agreement With Purdue Pharma (Canada) for the Licensing and Distribution Rights of BELBUCA in Canada
-Today, BioDelivery Sciences International Inc., a specialty pharmaceutical company with a focus in pain management and addiction medicine, and Purdue Pharma announce that they have signed an exclusive agreement for the licensing, distribution, marketing and sale of BELBUCA in Canada. Mark A. Sirgo, President and CEO, BioDelivery Sciences Intern
Articles(s): 1 - 25 of 236     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415